# electroCore, Inc.: overview ECOR · Nasdaq · CIK 1560258 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/ecor.md) · [Financials](/companies/ecor/financials.md) · [Filings](/companies/ecor/filings.md) · [Insiders](/companies/ecor/insiders.md) Latest reported revenue: [$9.4m](/filings/0001493152-26-036348.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-26-036348). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [6,554](/filings/0001493152-25-020884.md) | [7,046 d](/filings/0001493152-26-011636.md) | [6,719](/filings/0001493152-26-021495.md) | [7,381](/filings/0001493152-26-036348.md) | [8,689](/filings/0001493152-25-020884.md) | [9,243 d](/filings/0001493152-26-011636.md) | [9,584](/filings/0001493152-26-021495.md) | [9,450](/filings/0001493152-26-036348.md) | | Gross margin | % | [83.8%](/filings/0001493152-25-020884.md) | [85.9% d](/filings/0001493152-26-011636.md) | [84.9%](/filings/0001493152-26-021495.md) | [87.3%](/filings/0001493152-26-036348.md) | [86.0%](/filings/0001493152-25-020884.md) | [88.4% d](/filings/0001493152-26-011636.md) | [87.3%](/filings/0001493152-26-021495.md) | [86.5%](/filings/0001493152-26-036348.md) | | Operating margin | % | [(40.4%)](/filings/0001493152-25-020884.md) | [(43.6%) d](/filings/0001493152-26-011636.md) | [(56.9%)](/filings/0001493152-26-021495.md) | [(47.5%)](/filings/0001493152-26-036348.md) | [(33.2%)](/filings/0001493152-25-020884.md) | [(31.8%) d](/filings/0001493152-26-011636.md) | [(55.5%)](/filings/0001493152-26-021495.md) | [(29.3%)](/filings/0001493152-26-036348.md) | | Net margin | % | [(38.1%)](/filings/0001493152-25-020884.md) | [(45.8%) d](/filings/0001493152-26-011636.md) | [(57.4%)](/filings/0001493152-26-036348.md) | [(49.7%)](/filings/0001493152-26-036348.md) | [(39.2%)](/filings/0001493152-25-020884.md) | [(32.8%) d](/filings/0001493152-26-011636.md) | [(55.0%)](/filings/0001493152-26-036348.md) | [(32.4%)](/filings/0001493152-26-036348.md) | | Diluted EPS | $ per share | [(0.31)](/filings/0001493152-25-020884.md) | not reported | [(0.47)](/filings/0001493152-26-021495.md) | [(0.44)](/filings/0001493152-26-036348.md) | [(0.40)](/filings/0001493152-25-020884.md) | not reported | [(0.59)](/filings/0001493152-26-021495.md) | [(0.33)](/filings/0001493152-26-036348.md) | | Free cash flow | $k | not reported | not reported | [(4,392)](/filings/0001493152-26-021495.md) | [(648) d](/filings/0001493152-26-036348.md) | [(1,673) d](/filings/0001493152-25-020884.md) | [(1,540) d](/filings/0001493152-26-011636.md) | [(3,010)](/filings/0001493152-26-021495.md) | [(3,522) d](/filings/0001493152-26-036348.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [5.5](/filings/0001213900-23-018560.md) | [8.6](/filings/0001213900-24-022212.md) | [16.0](/filings/0001213900-25-023259.md) | [25.2](/filings/0001493152-26-011636.md) | [32.0](/filings/0001493152-26-011636.md) | | Gross margin | % | [74.6%](/filings/0001213900-23-018560.md) | [81.2%](/filings/0001213900-24-022212.md) | [82.5%](/filings/0001213900-25-023259.md) | [85.0%](/filings/0001493152-26-011636.md) | [86.8%](/filings/0001493152-26-011636.md) | | Operating margin | % | [(367.7%)](/filings/0001213900-23-018560.md) | [(266.2%)](/filings/0001213900-24-022212.md) | [(120.2%)](/filings/0001213900-25-023259.md) | [(48.3%)](/filings/0001493152-26-011636.md) | [(41.1%)](/filings/0001493152-26-011636.md) | | Net margin | % | [(315.9%)](/filings/0001213900-23-018560.md) | [(257.9%)](/filings/0001213900-24-022212.md) | [(117.5%)](/filings/0001213900-25-023259.md) | [(47.2%)](/filings/0001493152-26-011636.md) | [(43.6%)](/filings/0001493152-26-011636.md) | | Diluted EPS | $ per share | [(4.36)](/filings/0001213900-23-018560.md) | [(4.69)](/filings/0001213900-24-022212.md) | [(3.42)](/filings/0001213900-25-023259.md) | [(1.59)](/filings/0001493152-26-011636.md) | [(1.65)](/filings/0001493152-26-011636.md) | | Free cash flow | $m | not reported | not reported | [(14.9)](/filings/0001213900-25-023259.md) | not reported | [(8.3)](/filings/0001493152-26-011636.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ecor/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.8m | 211,639 | | Added +8,995 | | [FourWorld Capital Management LLC](/funds/1770525.md) | 2026-06-30 | $812.2k | 94,000 | | New +94,000 | | [WEXFORD CAPITAL LP](/funds/1048462.md) | 2026-06-30 | $795.4k | 92,060 | | New +92,060 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $632.2k | 73,149 | | Reduced −4,934 | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $574.6k | 66,506 | | Added +55,389 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $547.8k | 63,402 | | New +63,402 | | [Wealthspire Advisors, LLC](/funds/1646247.md) | 2026-06-30 | $410.4k | 47,498 | | Unchanged | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $378.5k | 43,803 | | New +43,803 | | [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $377.3k | 43,672 | | New +43,672 | | [Jaffetilchin Investment Partners, LLC](/funds/1404652.md) | 2026-03-31 | $350.9k | 58,198 | | Not compared | ## Recent filings [All 489 filings](/companies/ecor/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-09 | 08:30 ET | [8-K](/filings/0001493152-26-041893.md) | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-041893 | | 2026-08-06 | 16:16 ET | [10-Q](/filings/0001493152-26-036348.md) | Quarterly report, period 2026-06-30 | 0001493152-26-036348 | | 2026-08-06 | 16:11 ET | [8-K](/filings/0001493152-26-036342.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-036342 | | 2026-07-20 | 16:05 ET | [DEF 14A](/filings/0001493152-26-033907.md) | Proxy statement, period 2026-07-20 | 0001493152-26-033907 | | 2026-05-06 | 16:21 ET | [10-Q](/filings/0001493152-26-021495.md) | Quarterly report, period 2026-03-31 | 0001493152-26-021495 | | 2026-05-06 | 16:15 ET | [8-K](/filings/0001493152-26-021493.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-021493 | | 2026-03-19 | 16:35 ET | [10-K](/filings/0001493152-26-011636.md) | Annual report, period 2025-12-31 | 0001493152-26-011636 | | 2026-03-19 | 16:10 ET | [8-K](/filings/0001493152-26-011620.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-011620 | | 2026-01-20 | 16:05 ET | [8-K](/filings/0001493152-26-002847.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-002847 | | 2025-11-05 | 16:26 ET | [10-Q](/filings/0001493152-25-020884.md) | Quarterly report, period 2025-09-30 | 0001493152-25-020884 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-011636.md), filed Mar 19, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/65a563a1-68a6-4f4f-b8ce-7cf1ba498143) ## About the filer - CIK: 1560258 - Tickers: ECOR - Exchange: Nasdaq - SIC code: 3845 Electromedical & Electrotherapeutic Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.